金迪克2025年度归母净亏损1.73亿元

Core Viewpoint - The company reported a significant increase in revenue for the fiscal year 2025, but also experienced a substantial net loss attributed to increased R&D expenses and asset impairment provisions [1] Financial Performance - The company's revenue for 2025 reached 113 million, representing a year-on-year growth of 40.13% [1] - The net loss attributable to the parent company was 173 million, compared to a loss of 93.5 million in the same period last year [1] - Key financial metrics such as operating profit, total profit, and net profit attributable to the parent company showed significant fluctuations due to increased R&D investment and inventory write-offs [1] Operational Insights - The revenue growth was driven by proactive production scheduling, improved departmental coordination, and enhanced production efficiency, particularly in the flu vaccine segment [1] - The company focused on deepening customer service, optimizing marketing management systems, and expanding into new markets to increase product coverage [1]